Key terms
About WINT
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest WINT news
Yesterday
8:07am ET
Windtree Therapeutics announces 1-for-18 reverse stock split
Apr 17
8:03am ET
Windtree Therapeutics reports Q4 EPS (95c) vs ($13.01) last year
Apr 08
5:08pm ET
Windtree Therapeutics enters asset purchase deal with Varian Biopharmaceuticals
Feb 16
5:24pm ET
Windtree Therapeutics CFO Resigns Amid Cost-Cutting Measures
Feb 14
5:42pm ET
Windtree Therapeutics files to sell 608,272 shares of common stock for holders
Feb 01
8:08am ET
Windtree Therapeutics renews agreement with Chang Gung University
Jan 31
8:06am ET
Windtree Therapeutics engages Ladenburg to evaluate strategic alternatives
Jan 26
4:13am ET
Windtree Therapeutics Announces Equity Sales Filing Update
Jan 26
4:13am ET
Windtree Therapeutics Revises Agreement with Deerfield Management
Jan 25
8:40am ET
Windtree Therapeutics eliminates $15M contingent liability to Deerfield
No recent press releases are available for WINT
WINT Financials
Key terms
Ad Feedback
WINT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
WINT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
